BR9405858A - Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos - Google Patents

Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos

Info

Publication number
BR9405858A
BR9405858A BR9405858A BR9405858A BR9405858A BR 9405858 A BR9405858 A BR 9405858A BR 9405858 A BR9405858 A BR 9405858A BR 9405858 A BR9405858 A BR 9405858A BR 9405858 A BR9405858 A BR 9405858A
Authority
BR
Brazil
Prior art keywords
mammals
growth
affect
compositions
composite
Prior art date
Application number
BR9405858A
Other languages
English (en)
Inventor
Elliot Barnathan
Mary Osbakken
Shunichiro Okada
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR9405858A publication Critical patent/BR9405858A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9405858A 1993-03-31 1994-03-31 Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos BR9405858A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4049893A 1993-03-31 1993-03-31
PCT/US1994/003559 WO1994022455A1 (en) 1993-03-31 1994-03-31 Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor

Publications (1)

Publication Number Publication Date
BR9405858A true BR9405858A (pt) 1995-12-12

Family

ID=21911287

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9405858A BR9405858A (pt) 1993-03-31 1994-03-31 Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos

Country Status (6)

Country Link
EP (1) EP0697874A1 (pt)
JP (1) JPH08511041A (pt)
AU (1) AU6553994A (pt)
BR (1) BR9405858A (pt)
CA (1) CA2159717A1 (pt)
WO (1) WO1994022455A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
AU2003220685A1 (en) * 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
WO2004058786A1 (en) * 2002-12-31 2004-07-15 Council Of Scientific And Industrial Research Process for the synthesis of 2-deoxy-d-glucose
EP1735326A4 (en) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL TOXIN OF ANTHRAX
US7795227B2 (en) * 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
JP5888746B2 (ja) * 2010-08-24 2016-03-22 国立大学法人 宮崎大学 マトリックスメタロプロテアーゼ活性抑制組成物
TW201617084A (zh) * 2014-09-25 2016-05-16 山口龍二 包含β－環糊精之抗腫瘤劑
CN113057960B (zh) * 2021-04-15 2022-06-21 浙江理工大学 β-环糊精类衍生化合物在制备促进伤口愈合药物或制剂中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS5036422A (pt) * 1973-08-07 1975-04-05
US4020160A (en) * 1975-08-15 1977-04-26 American Cyanamid Company Cyclodextrin sulfate salts as complement inhibitors
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US4258180A (en) * 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
HU190584B (en) * 1983-03-11 1986-09-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara,Rt,Hu Process for the production of heptakis/2,6-di-o-methyl-beta-cyclodextrin
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
IL88970A (en) * 1988-01-19 1993-05-13 Folkman Moses Judah Composition for growth inhibiting comprising a cyclodextrine together with steroidal or non- steroidal growth- inhibiting compound
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
ES2059571T3 (es) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
US4902788A (en) * 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
DK0447171T3 (da) * 1990-03-15 1994-12-12 Tanabe Seiyaku Co Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf

Also Published As

Publication number Publication date
WO1994022455A1 (en) 1994-10-13
JPH08511041A (ja) 1996-11-19
EP0697874A1 (en) 1996-02-28
AU6553994A (en) 1994-10-24
CA2159717A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
MX9100423A (es) Composiciones liquidas y estabilizadas para el tratamiento de la piel y fibras
AR240015A1 (es) Composicion cosmetica que se opone al envejecimiento de la piel y procedimiento para su preparacion
BR9406178A (pt) Composição de amino-açucar e glicosaminoglicano para o tratamento e restauração de tecido conectivo
BR9206736A (pt) Composição para afetar o crescimento de tecido vivo em mamíferos processos para promover a angiogenese em mamíferos para tratar tecido transplantado ou órgãos em mamíferos e para tratar osso danificado ou transplantado
MX7531E (es) Proceso biotecnologico para alterar la proliferacion y/o el desarrollo de cultivos tisulares
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
BR9707425A (pt) Composto processo terapêutico para inibir o crescimento de células cancerosas e processo para utilizar o composto
BR8900357A (pt) Composicao e processo de tratamento de tecido e processo para a preparacao da dita composicao
MX9206953A (es) Composiciones fisiologicas de lagrima y metodos para su preparacion
EP0441639A3 (en) Instrument for the application of controlled mechanical loads to tissues in sterile culture
BR9708797A (pt) Processo de preparação de partículas as respectivas partículas e utilização das mesmas
BR9607808A (pt) Composição para limpeza da pele e processo para realçar o efeito antimicrobiano das formulações para limpeza da pele
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
BR9510509A (pt) Composto composição farmacêutica ou cosmética uso de uma composição e processo para prevenir e/ou combater o envelhecimento da pele
PL323797A1 (en) Application of bisulphonates to prevent bone tissue loss associated with immunosuppressive therapy
BR9702898A (pt) Utilização de um copolímero composição base para a pele processo para limitar diminuir e/ou impedir a transferência de uma composição e processo de maquilagem de pele
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9405858A (pt) Processos de afetar o crescimento de tecido vivo em mamiferos compostos e composiçÕes para os mesmos
ITRM970731A1 (it) Composizione per il trattamento di ustioni eritemi solari abrasioni piaghe e irritazioni cutanee
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE10084458T1 (de) Absorptionsfähige Gewebe zur Verbesserung der Hautschutzschicht
DE68916197D1 (de) Zusammensetzung zur in-vivo bzw. in-vitro steigerung des melaningehaltes der melanocyten und deren in-vitro verwendung.
PT935692E (pt) Tratamento de tecido com celulase e oxidoredutase
ITMI921223A1 (it) Composizioni poliestere/isocianato reticolabili adatte alla preparazione di manufatti in composito particolarmente con processi ad iniezione, procedimento per la loro preparazione e loro utilizzo

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/7004 (2006.01), A61K 31/00 (2006.0